AnaptysBio (ANAB) Competitors $19.00 -1.17 (-5.80%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ANAB vs. ALBO, ARWR, IDYA, KROS, WVE, NAMS, CGON, TWST, AMPH, and MIRMShould you be buying AnaptysBio stock or one of its competitors? The main competitors of AnaptysBio include Albireo Pharma (ALBO), Arrowhead Pharmaceuticals (ARWR), IDEAYA Biosciences (IDYA), Keros Therapeutics (KROS), Wave Life Sciences (WVE), NewAmsterdam Pharma (NAMS), CG Oncology (CGON), Twist Bioscience (TWST), Amphastar Pharmaceuticals (AMPH), and Mirum Pharmaceuticals (MIRM). These companies are all part of the "medical" sector. AnaptysBio vs. Albireo Pharma Arrowhead Pharmaceuticals IDEAYA Biosciences Keros Therapeutics Wave Life Sciences NewAmsterdam Pharma CG Oncology Twist Bioscience Amphastar Pharmaceuticals Mirum Pharmaceuticals Albireo Pharma (NASDAQ:ALBO) and AnaptysBio (NASDAQ:ANAB) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, community ranking, valuation, earnings and risk. Does the media favor ALBO or ANAB? In the previous week, AnaptysBio had 10 more articles in the media than Albireo Pharma. MarketBeat recorded 10 mentions for AnaptysBio and 0 mentions for Albireo Pharma. AnaptysBio's average media sentiment score of 0.32 beat Albireo Pharma's score of 0.20 indicating that AnaptysBio is being referred to more favorably in the news media. Company Overall Sentiment Albireo Pharma Neutral AnaptysBio Neutral Which has more risk and volatility, ALBO or ANAB? Albireo Pharma has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500. Comparatively, AnaptysBio has a beta of -0.24, indicating that its share price is 124% less volatile than the S&P 500. Which has higher earnings and valuation, ALBO or ANAB? Albireo Pharma has higher revenue and earnings than AnaptysBio. Albireo Pharma is trading at a lower price-to-earnings ratio than AnaptysBio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlbireo Pharma$40.58M22.52-$34.03M-$6.72-6.57AnaptysBio$17.16M33.69-$163.62M-$6.08-3.13 Do institutionals & insiders believe in ALBO or ANAB? 94.3% of Albireo Pharma shares are held by institutional investors. 6.9% of Albireo Pharma shares are held by insiders. Comparatively, 33.7% of AnaptysBio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the MarketBeat Community favor ALBO or ANAB? AnaptysBio received 65 more outperform votes than Albireo Pharma when rated by MarketBeat users. Likewise, 66.12% of users gave AnaptysBio an outperform vote while only 54.38% of users gave Albireo Pharma an outperform vote. CompanyUnderperformOutperformAlbireo PharmaOutperform Votes29854.38% Underperform Votes25045.62% AnaptysBioOutperform Votes36366.12% Underperform Votes18633.88% Do analysts recommend ALBO or ANAB? AnaptysBio has a consensus target price of $54.64, suggesting a potential upside of 187.56%. Given AnaptysBio's stronger consensus rating and higher possible upside, analysts plainly believe AnaptysBio is more favorable than Albireo Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Albireo Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00AnaptysBio 0 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.83 Is ALBO or ANAB more profitable? Albireo Pharma has a net margin of -228.51% compared to AnaptysBio's net margin of -289.75%. Albireo Pharma's return on equity of -97.13% beat AnaptysBio's return on equity.Company Net Margins Return on Equity Return on Assets Albireo Pharma-228.51% -97.13% -46.89% AnaptysBio -289.75%-287.94%-37.25% SummaryAnaptysBio beats Albireo Pharma on 12 of the 18 factors compared between the two stocks. Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Get AnaptysBio News Delivered to You Automatically Sign up to receive the latest news and ratings for ANAB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANAB vs. The Competition Export to ExcelMetricAnaptysBioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$578.17M$6.48B$5.12B$8.72BDividend YieldN/A8.13%5.18%4.07%P/E Ratio-3.135.6972.8114.16Price / Sales33.69349.551,250.2081.71Price / CashN/A53.3440.7036.03Price / Book6.869.606.455.94Net Income-$163.62M$154.43M$119.73M$225.73M7 Day Performance-10.84%-9.46%-5.13%-1.34%1 Month Performance-45.99%-7.27%-2.71%1.15%1 Year Performance27.52%28.13%31.08%24.02% AnaptysBio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANABAnaptysBio2.5896 of 5 stars$19.00-5.8%$54.64+187.6%+33.2%$578.17M$17.16M-3.13100Analyst ForecastALBOAlbireo PharmaN/A$44.15-0.2%N/A+0.0%$913.91M$40.58M-6.57130ARWRArrowhead Pharmaceuticals3.7112 of 5 stars$18.57-13.3%N/A-28.7%$2.31B$240.74M-3.98400Analyst UpgradeNews CoverageIDYAIDEAYA Biosciences4.191 of 5 stars$26.64-9.6%N/A-11.0%$2.30B$23.39M-11.4380KROSKeros Therapeutics3.6046 of 5 stars$56.62-6.2%N/A+79.9%$2.29B$150,000.00-10.87100WVEWave Life Sciences4.8719 of 5 stars$13.67-8.9%N/A+149.0%$2.29B$113.31M-12.32240Analyst ForecastInsider SellingShort Interest ↑Analyst RevisionNews CoverageNAMSNewAmsterdam Pharma3.0191 of 5 stars$24.90-0.3%N/A+150.5%$2.25B$33.59M0.0057Short Interest ↑News CoverageHigh Trading VolumeCGONCG Oncology3.1968 of 5 stars$32.90-7.3%N/AN/A$2.21B$650,000.000.0061Earnings ReportAnalyst ForecastShort Interest ↓Analyst RevisionNews CoveragePositive NewsTWSTTwist Bioscience3.6571 of 5 stars$36.89-5.3%N/A+93.4%$2.16B$245.11M-9.66990Upcoming EarningsInsider SellingNews CoverageHigh Trading VolumeAMPHAmphastar Pharmaceuticals4.88 of 5 stars$44.61-1.0%N/A-20.6%$2.14B$644.40M14.871,761Insider SellingMIRMMirum Pharmaceuticals4.2693 of 5 stars$44.50-3.8%N/A+46.8%$2.14B$264.38M-22.03140Earnings ReportAnalyst ForecastInsider SellingAnalyst RevisionNews Coverage Related Companies and Tools Related Companies Albireo Pharma Competitors Arrowhead Pharmaceuticals Competitors IDEAYA Biosciences Competitors Keros Therapeutics Competitors Wave Life Sciences Competitors NewAmsterdam Pharma Competitors CG Oncology Competitors Twist Bioscience Competitors Amphastar Pharmaceuticals Competitors Mirum Pharmaceuticals Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ANAB) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AnaptysBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AnaptysBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ANAB Stock Alerts